Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts. Show more
Location: 451 D Street, Boston, MA, 02210, United States | Website: https://elicio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
123.5M
52 Wk Range
$3.34 - $9.99
Previous Close
$7.72
Open
$7.80
Volume
13,520
Day Range
$7.72 - $7.89
Enterprise Value
110.8M
Cash
18.35M
Avg Qtr Burn
-8.766M
Insider Ownership
45.12%
Institutional Own.
10.45%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ELI-002 2P Details Solid tumor/s, Cancer | Phase 2 Update | |
ELI-002 7P Details Pancreatic cancer, Cancer | Phase 1/2 Data readout |